|
DSP Healthcare Fund An open ended equity scheme investing in healthcare and pharmaceutical sector |
|
|
Aditya Khemka
Total work experience of 11 years.
Managing this Scheme since
November 2018.
Vinit Sambre
Total work experience of 19 years.
Managing this Scheme since
November 2018.
Jay Kothari (Dedicated Fund
Manager for overseas investments)
Total work experience of 14 years.
Managing this Scheme since
November 2018.
Nov 30, 2018
S&P BSE HEALTHCARE (TRI)
| Regular Plan | |
| Growth: | ₹ 16.280 |
| Direct Plan | |
| Growth: | ₹ 16.795 |
₹ 708 Cr
₹ 666 Cr
0.17
| Regular Plan : | 2.45% |
| Direct Plan : | 1.00% |
Holding period <12 months: 1%
Holding period >=12 months: Nil
| Name of Instrument | % to Net Assets |
| EQUITY & EQUITY RELATED | |
| Listed / awaiting listing on the stock exchanges | |
| Pharmaceuticals | 69.57 |
| ✔ IPCA Laboratories Limited | 8.05 |
| ✔ Dr. Reddy's Laboratories Limited | 7.85 |
| ✔ Cipla Limited | 7.49 |
| ✔ Divi's Laboratories Limited | 6.79 |
| ✔ JB Chemicals & Pharmaceuticals Limited | 5.95 |
| ✔ Aarti Drugs Limited | 5.29 |
| ✔ Procter & Gamble Health Limited | 4.96 |
| ✔ Jubilant Life Sciences Limited | 3.40 |
| Alkem Laboratories Limited | 3.35 |
| Torrent Pharmaceuticals Limited | 3.35 |
| Syngene International Limited | 3.11 |
| Indoco Remedies Limited | 2.69 |
| Alembic Pharmaceuticals Limited | 2.46 |
| Unichem Laboratories Limited | 2.23 |
| Abbott India Limited | 1.46 |
| Ajanta Pharma Limited | 1.14 |
| Healthcare Services | 12.86 |
| Apollo Hospitals Enterprise Limited | 3.28 |
| Dr. Lal Path Labs Ltd. | 3.24 |
| Narayana Hrudayalaya Ltd. | 3.01 |
| Max Healthcare Institute Ltd | 2.92 |
| Max India Limited | 0.40 |
| Finance | 2.55 |
| ICICI Lombard General Insurance Company Limited | 2.55 |
| Total | 84.97 |
| Foreign Securitiesand/or overseas ETF(s) | |
| Listed / awaiting listing on the stock exchanges | |
| Pharmaceuticals | 7.09 |
| ✔ Abbott Laboratories | 3.64 |
| ✔ Intuitive Surgical Inc | 3.44 |
| Healthcare Services | 2.99 |
| Abiomed Inc | 2.99 |
| Total | 10.07 |
| MONEY MARKET INSTRUMENTS | |
| TREPS / Reverse Repo Investments / Corporate Debt Repo | 4.77 |
| Total | 4.77 |
| Cash & Cash Equivalent | |
| Net Receivables/Payables | 0.19 |
| Total | 0.19 |
| GRAND TOTAL | 100.00 |
✔ Top Ten Holdings
| Positions Exited |
| Healthcare Services |
| Advaita Allied Health Services Limited |
| New Position Bought |
| Healthcare Services |
| Max India Limited |
| Positions Increased |
| Pharmaceuticals |
| Alkem Laboratories Limited |
| Procter & Gamble Health Limited |
| Cipla Limited |
| Syngene International Limited |
| Torrent Pharmaceuticals Limited |
| Dr. Reddy's Laboratories Limited |
| IPCA Laboratories Limited |
| Healthcare Services |
| Apollo Hospitals Enterprise Limited |
| Dr. Lal Path Labs Ltd. |
| Narayana Hrudayalaya Ltd. |
| Positions Decreased |
| Pharmaceuticals |
| JB Chemicals & Pharmaceuticals Limited |
Rebalances below 0.05 % are not considered.
The primary investment objective of the
scheme is to seek to generate consistent
returns by predominantly investing in
equity and equity related securities of
pharmaceutical and healthcare companies.
However, there can be no assurance that
the investment objective of the scheme will
be realized.
This open ended equity Scheme is suitable for investors who are seeking*
• Long term capital growth
• Investment in equity and equity related Securities of healthcare and pharmaceutical companies
* Investors should consult their financial advisors if in doubt whether the product is suitable for them.